248 related articles for article (PubMed ID: 21182472)
1. FK506 binding proteins as targets in anticancer therapy.
Romano S; Di Pace A; Sorrentino A; Bisogni R; Sivero L; Romano MF
Anticancer Agents Med Chem; 2010 Nov; 10(9):651-6. PubMed ID: 21182472
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins.
Weiwad M; Edlich F; Kilka S; Erdmann F; Jarczowski F; Dorn M; Moutty MC; Fischer G
Biochemistry; 2006 Dec; 45(51):15776-84. PubMed ID: 17176100
[TBL] [Abstract][Full Text] [Related]
4. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.
Fruman DA; Wood MA; Gjertson CK; Katz HR; Burakoff SJ; Bierer BE
Eur J Immunol; 1995 Feb; 25(2):563-71. PubMed ID: 7533090
[TBL] [Abstract][Full Text] [Related]
5. Large FK506-binding proteins shape the pharmacology of rapamycin.
März AM; Fabian AK; Kozany C; Bracher A; Hausch F
Mol Cell Biol; 2013 Apr; 33(7):1357-67. PubMed ID: 23358420
[TBL] [Abstract][Full Text] [Related]
6. The effect of FK506 on transforming growth factor beta signaling and apoptosis in chronic lymphocytic leukemia B cells.
Romano S; Mallardo M; Chiurazzi F; Bisogni R; D'Angelillo A; Liuzzi R; Compare G; Romano MF
Haematologica; 2008 Jul; 93(7):1039-48. PubMed ID: 18492692
[TBL] [Abstract][Full Text] [Related]
7. FKBPs in chromatin modification and cancer.
Yao YL; Liang YC; Huang HH; Yang WM
Curr Opin Pharmacol; 2011 Aug; 11(4):301-7. PubMed ID: 21489876
[TBL] [Abstract][Full Text] [Related]
8. FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention.
Annett S; Moore G; Robson T
Pharmacol Ther; 2020 Nov; 215():107623. PubMed ID: 32622856
[TBL] [Abstract][Full Text] [Related]
9. FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506.
Xu X; Su B; Barndt RJ; Chen H; Xin H; Yan G; Chen L; Cheng D; Heitman J; Zhuang Y; Fleischer S; Shou W
Transplantation; 2002 Jun; 73(11):1835-8. PubMed ID: 12085010
[TBL] [Abstract][Full Text] [Related]
10. The antimalarial action of FK506 and rapamycin: evidence for a direct effect on FK506-binding protein PfFKBP35.
Monaghan P; Leneghan DB; Shaw W; Bell A
Parasitology; 2017 Jun; 144(7):869-876. PubMed ID: 28274284
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of large immunophilin FK506 binding protein 51 in cancer.
Romano S; Sorrentino A; Di Pace AL; Nappo G; Mercogliano C; Romano MF
Curr Med Chem; 2011; 18(35):5424-9. PubMed ID: 22087835
[TBL] [Abstract][Full Text] [Related]
12. Calcium- and FK506-independent interaction between the immunophilin FKBP51 and calcineurin.
Li TK; Baksh S; Cristillo AD; Bierer BE
J Cell Biochem; 2002; 84(3):460-71. PubMed ID: 11813252
[TBL] [Abstract][Full Text] [Related]
13. FK506, an immunosuppressant targeting calcineurin function.
Dumont FJ
Curr Med Chem; 2000 Jul; 7(7):731-48. PubMed ID: 10702636
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells.
Cho CS; Chang Z; Elkahwaji J; Scheunemann TL; Manthei ER; Colburn M; Knechtle SJ; Hamawy MM
Int Immunol; 2003 Nov; 15(11):1369-78. PubMed ID: 14565935
[TBL] [Abstract][Full Text] [Related]
15. FKBP family proteins: immunophilins with versatile biological functions.
Kang CB; Hong Y; Dhe-Paganon S; Yoon HS
Neurosignals; 2008; 16(4):318-25. PubMed ID: 18635947
[TBL] [Abstract][Full Text] [Related]
16. Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans.
Arndt C; Cruz MC; Cardenas ME; Heitman J
Microbiology (Reading); 1999 Aug; 145 ( Pt 8)():1989-2000. PubMed ID: 10463165
[TBL] [Abstract][Full Text] [Related]
17. FKBPs and the Akt/mTOR pathway.
Hausch F; Kozany C; Theodoropoulou M; Fabian AK
Cell Cycle; 2013 Aug; 12(15):2366-70. PubMed ID: 23839048
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25.
Johnson KL; Lawen A
Immunol Cell Biol; 1999 Jun; 77(3):242-8. PubMed ID: 10361256
[TBL] [Abstract][Full Text] [Related]
19. Cellular signaling mechanisms for stimulation of growth hormone secretion and growth hormone primary transcripts by immunosuppressant agents, FK506 and cyclosporin A, in cultured rat pituitary cells.
Ohye H; Sato M; Murao K; Matsubara S; Tokuda M; Takahara J
Neuroimmunomodulation; 1998; 5(6):309-17. PubMed ID: 9762012
[TBL] [Abstract][Full Text] [Related]
20. The FKBP-associated protein FAP48 is an antiproliferative molecule and a player in T cell activation that increases IL2 synthesis.
Krummrei U; Baulieu EE; Chambraud B
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2444-9. PubMed ID: 12604780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
